ABOS
Price
$2.17
Change
+$0.02 (+0.93%)
Updated
Jun 8 closing price
Capitalization
156.73M
69 days until earnings call
Intraday BUY SELL Signals
EVAX
Price
$3.73
Change
+$0.18 (+5.07%)
Updated
Jun 8 closing price
Capitalization
32.19M
Intraday BUY SELL Signals
Interact to see
Advertisement

ABOS vs EVAX

Header iconABOS vs EVAX Comparison
Open Charts ABOS vs EVAXBanner chart's image
ABOS vs EVAX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ABOS vs. EVAX commentary
Jun 09, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABOS is a Hold and EVAX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 09, 2026
Stock price -- (ABOS: $2.17 vs. EVAX: $3.86)
Brand notoriety: ABOS and EVAX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABOS: 64% vs. EVAX: 63%
Market capitalization -- ABOS: $156.73M vs. EVAX: $32.19M
ABOS [@Biotechnology] is valued at $156.73M. EVAX’s [@Biotechnology] market capitalization is $32.19M. The market cap for tickers in the [@Biotechnology] industry ranges from $112.43B to $0. The average market capitalization across the [@Biotechnology] industry is $1.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABOS’s FA Score shows that 0 FA rating(s) are green whileEVAX’s FA Score has 1 green FA rating(s).

  • ABOS’s FA Score: 0 green, 5 red.
  • EVAX’s FA Score: 1 green, 4 red.
According to our system of comparison, EVAX is a better buy in the long-term than ABOS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABOS’s TA Score shows that 4 TA indicator(s) are bullish while EVAX’s TA Score has 4 bullish TA indicator(s).

  • ABOS’s TA Score: 4 bullish, 5 bearish.
  • EVAX’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ABOS is a better buy in the short-term than EVAX.

Price Growth

ABOS (@Biotechnology) experienced а -13.55% price change this week, while EVAX (@Biotechnology) price change was -1.03% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.10%. For the same industry, the average monthly price growth was -7.08%, and the average quarterly price growth was -4.86%.

Reported Earning Dates

ABOS is expected to report earnings on Aug 17, 2026.

Industries' Descriptions

@Biotechnology (-7.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABOS($157M) has a higher market cap than EVAX($32.2M). ABOS YTD gains are higher at: 2.844 vs. EVAX (-19.078). EVAX has higher annual earnings (EBITDA): -9.88M vs. ABOS (-108.82M). ABOS has more cash in the bank: 128M vs. EVAX (18.4M). EVAX has less debt than ABOS: EVAX (11.3M) vs ABOS (31.2M). EVAX has higher revenues than ABOS: EVAX (7.53M) vs ABOS (0).
ABOSEVAXABOS / EVAX
Capitalization157M32.2M488%
EBITDA-108.82M-9.88M1,102%
Gain YTD2.844-19.078-15%
P/E RatioN/AN/A-
Revenue07.53M-
Total Cash128M18.4M696%
Total Debt31.2M11.3M276%
TECHNICAL ANALYSIS
Technical Analysis
ABOSEVAX
RSI
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
81%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
88%
Momentum
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
89%
MACD
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 18 days ago
81%
Bullish Trend 14 days ago
84%
Declines
ODDS (%)
Bearish Trend 5 days ago
87%
Bearish Trend 6 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
82%
Aroon
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ABOS
Daily Signal:
Gain/Loss:
EVAX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MPLT29.511.50
+5.36%
MapLight Therapeutics Inc.
RCKY37.980.53
+1.42%
Rocky Brands
FNB17.710.02
+0.11%
FNB Corp
TMO469.63-3.17
-0.67%
Thermo Fisher Scientific
HPAI0.85-0.10
-10.59%
Helport AI Limited

ABOS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABOS has been loosely correlated with CCXI. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ABOS jumps, then CCXI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABOS
1D Price
Change %
ABOS100%
+0.93%
CCXI - ABOS
48%
Loosely correlated
-0.00%
CELC - ABOS
44%
Loosely correlated
-0.96%
NKTX - ABOS
42%
Loosely correlated
-4.38%
RCKT - ABOS
40%
Loosely correlated
-1.82%
CRBU - ABOS
37%
Loosely correlated
-3.91%
More

EVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, EVAX has been loosely correlated with OMER. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if EVAX jumps, then OMER could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EVAX
1D Price
Change %
EVAX100%
+8.73%
OMER - EVAX
40%
Loosely correlated
+0.61%
RXRX - EVAX
39%
Loosely correlated
+0.15%
ABSI - EVAX
37%
Loosely correlated
+2.34%
CYPH - EVAX
34%
Loosely correlated
+41.04%
NKTX - EVAX
32%
Poorly correlated
-4.38%
More